Cargando…
Treatment of malignant pleural effusions: the case for localized immunotherapy
Malignant pleural effusions (MPE) are a common terminal pathway for many cancers, with an estimated United States incidence of more than 150,000 cases per year. MPE is an aggressive disease with a uniformly fatal prognosis and a life expectancy of only 3 to 12 months. The development of an effective...
Autores principales: | Donnenberg, Albert D., Luketich, James D., Dhupar, Rajeev, Donnenberg, Vera S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472034/ https://www.ncbi.nlm.nih.gov/pubmed/30999958 http://dx.doi.org/10.1186/s40425-019-0590-4 |
Ejemplares similares
-
Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications
por: Donnenberg, Albert D., et al.
Publicado: (2019) -
A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells
por: Donnenberg, Vera S., et al.
Publicado: (2023) -
Delayed Chylothorax during Treatment of Follicular Lymphoma with a Malignant Pleural Effusion
por: Ekeke, Chigozirim N., et al.
Publicado: (2020) -
Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity
por: Donnenberg, Vera S., et al.
Publicado: (2022) -
KIT (CD117) Expression in a Subset of Non-Small Cell Lung Carcinoma (NSCLC) Patients
por: Donnenberg, Albert D., et al.
Publicado: (2012)